MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 3, 2015, Pages 499-505

  Choi, Ivy Y ^a   Gerlag, Danielle M ^a   Herenius, Marieke J ^a   Thurlings, Rogier M ^a   Wijbrandts, Carla A ^a   Foell, Dirk ^b   Vogl, Thomas ^b   Roth, Johannes ^b   Tak, Paul P ^a,c,d   Holzinger, Dirk ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN A; CALGRANULIN B; CLEMASTINE FUMARATE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE; PARACETAMOL; RHEUMATOID FACTOR; RITUXIMAB; ABC TRANSPORTER; ABCC11 PROTEIN, HUMAN; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT TOOL; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATIONAL STUDY; DAS28; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DOWN REGULATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; EUROPEAN LEAGUE AGAINST RHEUMATISM CRITERIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTIVE VALUE; PREMEDICATION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; COHORT ANALYSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; CALGRANULIN B; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922365213     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203923     Document Type: Article

References (42)

1. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000; 43:2619-33.
2. Emery P, Keystone E, Tony H.P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67:1516-23.
3. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114-23.
4. Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFalpha blocker failure. Biologics 2012; 6:191-9.
5. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011; 25:549-67.
6. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594-602.
7. Weinblatt ME, Kremer JM, Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
8. Weinblatt ME, Keystone EC, Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35-45.
9. Emery P, Deodhar A, Rigby W.F., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010; 69:1629-35.
10. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010; 49:1683-93.
11. Tak PP. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford) 2012; 51:600-9.
12. Boumans MJ, Thurlings RM, Gerlag D.M., et al. Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system. Arthritis Rheum 2011; 63:3187-94.
13. Gerlag DM, Haringman JJ, Smeets T.J., et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004; 50:3783-91.
14. Haringman JJ, Gerlag DM, Zwinderman A.H., et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:834-8.
15. Sampson B, Fagerhol MK, Sunderkotter C, et al. Hyperzincaemia and hypercalprotectinaemia: a new disorder of zinc metabolism. Lancet 2002; 360:1742-5.
16. Vogl T, Tenbrock K, Ludwig S., et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13:1042-9.
17. Chen YS, Yan W, Geczy C.L., et al. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009; 11:R39.
18. Loser K, Vogl T, Voskort M., et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 2010; 16:713-17.
19. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 1998; 160:1427-35.
20. Uchida T, Fukawa A, Uchida M., et al. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002; 1:495-9.
21. van Lent PL, Grevers L, Blom A.B., et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 2008; 67:1750-8.
22. Viemann D, Strey A, Janning A., et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005; 105:2955-62.
23. Vogl T, Ludwig S, Goebeler M., et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004; 104:4260-8.
24. Foell D, Wulffraat N, Wedderburn L.R., et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303:1266-73.
25. Holzinger D, Frosch M, Kastrup A., et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2012; 71:974-80.
26. Wittkowski H, Kuemmerle-Deschner JB, Austermann J., et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis 2011; 70:2075-81.
27. Thurlings RM, Vos K, Wijbrandts C.A., et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67:917-25.
28. Wijbrandts CA, Dijkgraaf MG, Kraan M.C., et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 2008; 67:1139-44.
29. Wijbrandts CA, van Leuven SI, Boom HD, et al. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68:1316-21.
30. Arnett FC, Edworthy SM, Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
31. van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999; 26:705-11.
32. Vos K, Thurlings RM, Wijbrandts C.A., et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:772-8.
33. Frosch M, Strey A, Vogl T., et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43:628-37.
34. Berntzen HB, Olmez U, Fagerhol M.K., et al. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991; 20:74-82.
35. Youssef P, Roth J, Frosch M., et al. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol 1999; 26:2523-8.
36. Gerlag DM, Tak PP. How to perform and analyse synovial biopsies. Best Pract Res Clin Rheumatol 2009; 23:221-32.
37. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004; 50:3762-71.
38. Gerss J, Roth J, Holzinger D., et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 2012; 71:1991-7.
39. Andres CL, Mann H, Pecha O., et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2011; 13:R122.
40. Hammer HB, Fagerhol MK, Wien T.N., et al. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther 2011; 13:R178.
41. Buch MH, Seto Y, Bingham S.J., et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005; 52:42-8.
42. Sekiguchi N, Kawauchi S, Furuya T., et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 2008; 47:780-8.